Connect With a Global Community of Experts
In the rapidly growing field of cannabinoid and ECS-targeting drug development, developers face challenges in sourcing, procuring, and supplying high-quality APIs that meet regulatory standards. This explains why in 2025 the need for innovative drug delivery techniques and robust clinical trial design was more pressing than ever.
At the 8th Cannabinoid & Endocannabinoid Drug Development Summit, we offered you a platform for showcasing your customized systems and innovative solutions. Our sponsors engaged with key stakeholders and decision-makers from NeuroTherapia, Ananda Pharma, NaluBio and more. They positioned their CRO, CDMO, supplier, or consulting services prominently to play a crucial role in driving progress.
With opportunities to present, network one-on-one with stakeholders, and elevate brand visibility, you can still explore a tailored partnership package for 2026 that aligns with your business objectives, ensuring your solution takes centre stage next year.
Why Partner?
1
Build connections with your target audience and secure new business: Connect with senior decision makers from biotech and pharma increasing their spend in cannabinoid R&D and CBR-targeting therapies.
2
Elevate your company’s brand awareness: Explore innovative ways to differentiate your brand and establish yourself as the go-to commercial partner for biotech and pharma entering the cannabinoid and ECS-targeting space.
3
Showcase your solutions and expertise: Capitalize on our highly engaged audience of biopharma stakeholders prioritizing preclinical & clinical research and actively asking for high-level support.
Audience Composition
Company Type
Attendee Seniority
2025 Companies That Attendeded